Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology jobs Pharmaceuticals STAT+addiction

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 15 days ago STAT+: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal - about 2 months ago STAT+: Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: AstraZeneca says China has detained a senior executive - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Denali Therapeutics spinout raises $200M as neuro company resets - 24 days ago STAT+: ‘Significant talent shortage’ threatens the rise of radiopharmaceuticals - 2 months ago STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger - 2 months ago STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 5 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 5 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 8 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 11 months ago STAT Virtual Event \| 2024 JPM Recap, Live! - about 1 year ago
3	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Galapagos to split itself into two companies as part of turnaround plan - 24 days ago STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study - 5 months ago STAT+: Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial - 5 months ago STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more - 5 months ago STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried - 8 months ago STAT+: A scientific mystery highlights the blind spots in genomics databases - 11 months ago STAT+: Results on Novartis prostate cancer therapy could expand its use - over 1 year ago STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit - over 1 year ago
4	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Google’s secretive anti-aging company Calico finally released data. Its drug failed - 26 days ago STAT+: Tome Biosciences files notice to lay off virtually entire staff - 5 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 5 months ago
5	Bob Herman STAT News Health care business reporter. Indiana Health carebusiness	STAT+: Employers step up to defend PBMs, and other fascinating lawsuits we’re watching - 26 days ago STAT+: Aetna lawsuit alleges radiology group of fraudulent billing and abuse of federal arbitration - about 1 month ago STAT+: A tough year for health insurance stocks as patients get more care - about 1 month ago STAT+: How often ‘value-based care’ is uttered on Wall Street - 2 months ago STAT+: Former UnitedHealth doctors detail what changed at their clinics after takeovers - 4 months ago STAT+: Medicare Advantage insurers ramped up use of technology to deny claims, Senate investigation shows - 4 months ago STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - 4 months ago STAT+: UnitedHealth sues Medicare to reverse downgraded star ratings - 4 months ago STAT+: Private equity firms to acquire health care billing and payments firm R1 in $8.9 billion deal - 6 months ago STAT+: Why health care spending keeps climbing - 8 months ago
6	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: Latest updates to hospital price transparency rules aim to make the data more useful - about 1 month ago STAT+: The dropped call that took down Centene’s Medicare Advantage star ratings - 3 months ago STAT+: For the behemoth UnitedHealth, a new threat to Medicare profits - 3 months ago STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - 4 months ago STAT+: Humana cutting Medicare Advantage plans that cover 10% of members - 5 months ago
7	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	STAT stories you might have missed in 2024 - about 1 month ago STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman - 11 months ago STAT stories you might have missed in 2023 - about 1 year ago STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D - about 1 year ago An Ask Me Anything with STAT’s Nicholas St. Fleur - over 1 year ago
8	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - about 2 months ago STAT+: Exact Sciences wins FDA approval for improved stool-based colon cancer test - 4 months ago STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 5 months ago STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending - 5 months ago
9	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - about 2 months ago STAT+: The end of 23andMe’s drug discovery dream - 3 months ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 8 months ago STAT+: Why Sanofi got shellacked - over 1 year ago
10	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments - about 2 months ago STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - 3 months ago STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 5 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 5 months ago STAT+: On Andrew Left and the government’s fraud case - 6 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 10 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 10 months ago STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch - about 1 year ago STAT Virtual Event \| Cancer’s Breakthrough Engine - about 1 year ago

Journalists covering STAT+